Drug intelligence / Profile preview

JNJ-87562761

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Unspecified (not Yet Disclosed; See Process)

Overview

JNJ-87562761 is an investigational antineoplastic agent being developed by Janssen Research & Development for the treatment of relapsed or refractory multiple myeloma. It is a new molecular entity currently in Phase 1 clinical trials. The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025. The drug is being evaluated in first-in-human studies to determine its recommended Phase 2 dose, safety, and tolerability in patients whose disease has returned after prior therapy or has not responded to standard treatments[1][2][3][4].

Beyond the preview

Go deeper on JNJ-87562761.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-87562761.

Explore the full profile